Summary & Overview
HCPCS G8881: Breast Cancer Stage Greater Than T1N0M0 or T2N0M0
HCPCS Level II code G8881 documents that a patient’s breast cancer stage is greater than T1N0M0 or T2N0M0, signaling disease beyond the specified early tumor and nodal classifications. Nationally, accurate staging drives treatment selection, eligibility for therapies, and quality reporting, making precise use of this code important for clinical records and payer adjudication.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical meaning, expected service settings, and how the code is used in billing and documentation workflows. The publication also outlines commonly observed payer coverage considerations and modifiers associated with oncology and procedural billing where available.
This summary provides benchmarks and policy context relevant to national billing practices, highlights where this staging designation intersects with oncology care pathways, and identifies gaps where further coding detail or supporting documentation is commonly required. Data not available in the input is noted where specifics such as associated taxonomies, ICD-10 mappings, and related codes are missing.
Billing Code Overview
HCPCS Level II code G8881 indicates that the stage of breast cancer is greater than T1N0M0 or T2N0M0. This code documents a clinical staging assessment that the primary tumor and nodal status exceed the specified early-stage thresholds.
Service Type: Cancer staging assessment / oncology diagnostic classification
Typical Site of Service: Oncology clinic, hospital outpatient department, or other cancer care settings
Clinical & Coding Specifications
Clinical Context
A typical patient is a 58-year-old woman recently diagnosed with invasive breast carcinoma whose pathology and imaging indicate a tumor stage greater than T1N0M0 or T2N0M0 (for example, T3N1M0 or node-positive disease). The patient presents to a multidisciplinary breast clinic after core biopsy confirmed invasive ductal carcinoma. Clinical workflow: history and physical exam by a surgical oncologist or breast surgeon; diagnostic breast and regional nodal imaging (diagnostic mammography, breast ultrasound, breast MRI, and/or chest CT or PET-CT as indicated) to stage the primary tumor and evaluate nodal/distant disease; multidisciplinary tumor board discussion including medical oncology, radiation oncology, radiology, and pathology to determine neoadjuvant therapy versus upfront surgery; documentation of pathologic and clinical stage in the medical record and operative notes; surgical planning for lumpectomy with axillary staging (sentinel lymph node biopsy or axillary dissection) or mastectomy as appropriate; perioperative anesthesia and post-operative follow-up. Typical site of service: hospital outpatient surgical department, ambulatory surgery center, or multidisciplinary oncology clinic. Typical patient scenario modifiers may include complex surgical work (22), unusual anesthesia (AS), or bilateral procedures if applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|